促进纳米载体肿瘤组织渗透性的研究进展

过去几十年里,抗肿瘤药物传输取得了巨大的进展,但是肿瘤的高效治疗依然是难啃的"硬骨头"。研究重点逐渐由载体肿瘤聚集向精确靶向、继而向肿瘤组织深处渗透性给药转移,特别是,如何克服种种障碍以实现其均匀地分布于整个肿瘤组织,达到有效的抗肿瘤药物浓度以更好地发挥疗效。本文从肿瘤组织渗透机理入手,探讨载体的粒径、Zeta电位、形状、结构与化学组成等因素对肿瘤组织渗透性的影响;介绍了多细胞球体模型、多层细胞培养与体内模型等肿瘤组织渗透性评价方法;并对载体在肿瘤组织渗透性方面的研究进行了展望。     

A melatonin-based targetable fluorescent probe for screening of tumor cells and real-time imaging of glutathione fluctuations in tumor cells

Glutathione(GSH) is a key maintainer of cellular redox balance and plays an important role in many physiological effects. For example, GSH has been widely implicated in cancer initiation, progression and metastasis. Moreover, the concentrations of GSH in tumor cells can influence drug resistance. Given the serious harmfulness of cancer and the important roles of GSH in cancer, it has great significance to development probes for screening of tumor cells and real-time monitoring of GSH fluctuation...     

pH敏感铱、钌和铂配合物在肿瘤靶向荧光成像和治疗中的应用

肿瘤组织的微酸性环境为肿瘤准确诊断和有效治疗提供了新思路。pH敏感性金属配合物因具有较高的物理化学稳定性,突出的光谱特性和肿瘤靶向性等性质,引起高度关注。本文综述了这种肿瘤酸性微环境的产生机制以及近年来对这种酸性微环境敏感的铱、钌、铂配合物作为肿瘤成像和治疗试剂的研究进展。     

氟硼二吡咯探针在肿瘤检测中的应用

目前,肿瘤是世界上死亡率最高的疾病之一,早期肿瘤细胞的检测对于肿瘤的预防和治疗具有重要意义。当前针对肿瘤细胞的检测手段主要有X光、计算机断层扫描(CT)、磁共振成像(MRI)等,但借助这些手段检测出来的肿瘤细胞通常已生长到中后期,极不利于肿瘤的治疗。荧光成像作为生命科学研究领域常用的手段之一,近年来被用于肿瘤细胞检测,与其他检测方法相比,具有微创、高效、低成本和更加灵敏等优势。氟硼二吡咯(BODIPY)荧光染料作为荧光成像的工具之一,因具有荧光量子产率高、稳定性好、易于修饰等独特优势,被广泛应用于肿瘤细胞检测领域。与常规检测手段相比,BODIPY探针可以靶向肿瘤细胞内细胞器或肿瘤标志物,达到检测早期肿瘤细胞的目的。本文综述了靶向不同标记分子的BODIPY探针的应用,并分析了BODIPY探针的作用机理,以期为肿瘤的临床检测提供更加方便、快捷、直观、灵敏的工具。     

DRUG and LIGHT DOSE DEPENDENCE OF PHOTODYNAMIC THERAPY: A STUDY OF TUMOR and NORMAL TISSUE RESPONSE

Abstract It is clinically relevant to determine drug and light dose combinations where complete tumor response is accompanied by little or no photosensitivity, and minimal damage to normal tissues. Although reciprocity of RIF tumor cell clonogenicity has been established within a range of drug and light doses, no quantitative data exist for reciprocity of tumor response. This study has examined reciprocity of drug and light doses for tumor response and normal tissue damage in two experimental mouse models. Representative tumors were examined for vascular damage after treatment. Reciprocity of drug and light doses for tumor response was observed over a range of drug/light combinations in both tumor models. Reciprocity failed when drug dose was reduced below a threshold value. For reciprocal drug/light combinations, complete vascular stasis occurred in the tumor and surrounding skin which was followed by necrosis of those tissues. In non-reciprocal PDT combinations, there was vascular damage to the tumor but no damage to the surrounding normal tissues. Tumors responded initially, but no cure was obtained. Tumor cure was only observed under conditions where a considerable margin of normal tissue surrounding the tumor was damaged. This conclusion was supported by shielding experiments done to assess the contribution of normal tissue damage to tumor response. Reciprocity of drug and light doses for tumor response was therefore shown to exist only at high drug doses, which were not low enough to reduce skin photosensitivity in our models.     

Protective Effect of Dermal Brimonidine Applications Against UV Radiation‐induced Skin Tumors,Epidermal Hyperplasia and Cell Proliferation in the Skin of Hairless Mice

Brimonidine at 0.18%, 1% and 2% concentrations applied topically in hairless mice significantly decreased tumor burden and incidences of erythema, flaking, wrinkling and skin thickening induced by UVR. The unbiased median week to tumor ≥1 mm was increased by the 1% and 2% concentrations. The tumor yield was reduced by all concentrations at week 40 for all tumor sizes but the ≥4 mm tumors with the 0.18% concentration. At week 52, the tumor yield was reduced for all tumor sizes and all brimonidine concentrations. The tumor incidence was reduced by all concentrations at week 40 for all tumor sizes, but the ≥4 mm tumor with the 0.18% concentration and at week 52 for all tumor sizes with the 1% and 2% concentrations and with the 0.18% concentration only for the ≥4 mm tumors. Reductions in ≥4 mm tumor incidences compared to the vehicle control group were 54%, 91% and 86% by week 52 for the 0.18%, 1% and 2% concentrations, respectively. Brimonidine at 2% applied 1 h before or just after UVB irradiation on hairless mice decreased epidermal hyperplasia by 23% and 32% and epithelial cell proliferation by 59% and 64%, respectively, similar to an epidermal growth factor receptor (EGFR) inhibitor.     

Mammary gland tumor promotion in F1 generation offspring from male and female rats exposed to soy isoflavones for a lifetime

The effect of dietary isoflavones in the form of NOVASOY (NS) was investigated on methylnitrosourea-initiated mammary gland cancer in F1 generation female Sprague Dawley rats from parents who had undergone lifetime exposure to variable levels of dietary NS. In comparison to NS-free dietary groups, lifetime exposure of F1 rats to 40 and 1000 mg/kg diets of NS reduced tumor latency, but did not significantly affect tumor incidence, tumor size, or tumor multiplicity. A significantly lower tumor multiplicity was, however, observed in rats fed the soy-based, NS-free diet compared to the casein-based, NS-free diet. An evaluation of a dose-response relationship pointed towards a biphasic effect, with a trend showing lower tumor incidence, lower tumor multiplicity, and lower tumor size in rats fed 1000 mg/kg diet NS compared to 40 mg/kg diet NS; however, the data failed to achieve statistical significance. Histologically, tumor type significantly differed according to the administered basal diet variety and NS dose. Our data and that of others provide conflicting evidence for chemopreventive effects of soy isoflavones on mammary gland tumor induction. We suggest standardization of interlaboratory experimental approaches for establishing low dose-response relationships for soy and its isoflavones to aid in risk assessment.     

Activation of macrophage tumoricidal activity by photodynamic treatment in vitro-indirect activation of macrophages by photodynamically killed tumor cells

Macrophages constitute a major part of natural tumor defense by their capacity to destroy selectively a broad range of tumor types upon specific activation. In the last couple of years, these cells have also been implicated as effector cells in the destruction of tumors by photodynamic therapy. In the present work, the potential role of macrophage-mediated tumor cytotoxicity after photodynamic treatment in vitro has been investigated with respect to photodynamic activation of macrophages for tumoricidal effector functions. Our data show that photodynamic treatment of highly pure murine bone-marrow-derived macrophages with the hematoporphyrin derivative Photosan-3 does not result in activation of these cells for cytotoxicity against YAC-1 tumor cells or secretion of tumor necrosis factor and nitric oxide, irrespective of co-stimulation with interferon-γ, a potent priming agent for macrophage antitumoral activity. On the contrary, treatment with higher photosensitizer doses is found to reduce markedly the viability of the macrophage effector cells. Thus, these results do not lend any support to the hypothesis of direct macrophage activation by photodynamic treatment. However, macrophages are found to be activated for tumoricidal effector functions indirectly by photodynamically killed tumor cells, in a way reminiscent of phagocytosis-inducing stimuli. It is thus suggested that recognition and phagocytosis of photodynamically destroyed tumor cells constitutes the major signal for local activation of macrophages in photodynamically treated tumor tissues, which may be crucial for final, specific eradication by the immune system of tumor cells surviving photodynamic treatment.     

Lipid-conjugated siRNA hitchhikes endogenous albumin for tumor immunotherapy

With the development of a small interfering RNA (siRNA) delivery strategy, increasing siRNA therapeutics for tumor treatment appeared in clinical trials and pre-clinical development. However, the test results of such therapeutics unveiled that efficient siRNA delivery to tumor tissues is still challenging. Albumin is considered an ideal carrier for delivering hydrophobic agents into tumor tissue because it is highly concentrated and long-circulating in blood and has propensity of tumor enrichment. Herein, we synthesized lipid conjugated siRNAs (LsiRNAs), which showed high affinity to albumin. Mechanistically, LsiRNAs non-covalently bind to the hydrophobic core of albumin through its octadecyl tails. The small size of albumin/LsiRNAs allows the complex to penetrate tumor tissue efficiently. Biodistribution test proved that albumin extremely prolonged circulation time and increased tumor retention of associated LsiRNAs. Notably, LsiRNA against programmed death ligand-1 (Pdl1) efficiently suppressed tumor growth as well as prolonged survival time of tumor bearing mice by increasing infiltration of CD8⁺ T cells as well as promoted the maturation of dendritic cells both in tumor and lymph. Together, LsiRNAs provide a simple but effective way for siRNA tumor delivery that “hitchhikes” on albumin.     

碳酸酐酶靶向探针的研究进展

碳酸酐酶作为一类在肿瘤中高表达的酶, 参与肿瘤组织中乏氧、 微酸性等环境的调节, 已成为肿瘤诊断与治疗的一类重要靶点. 本文简要概述了碳酸酐酶的生物学功能, 并总结了目前针对碳酸酐酶所构建的不同类型的分子探针, 以及其在肿瘤成像与治疗应用中的研究进展. 最后, 对靶向碳酸酐酶探针研究所面临的挑战和未来可能的研究方向进行了展望.     

An Enzyme-Loaded Metal–Organic Framework-Assisted Microfluidic Platform Enables Single-Cell Metabolite Analysis

Colonization of cancer cells at secondary sites, a decisive step in tumor metastasis, is strongly dependent on the formation of metastatic microenvironments regulated by intrinsic single-cell metabolism traits. Herein, we report a single-cell microfluidic platform for high-throughput dynamic monitoring of tumor cell metabolites to evaluate tumor malignancy. This microfluidic device empowers efficient isolation of single cells (>99 %) in a squashed state similar to tumor extravasation, and employs enzyme-packaged metal–organic frameworks to catalyze tumor cell metabolites for visualization. The microfluidic evaluation was confirmed by in vivo assays, suggesting that the platform allowed predicting the tumorigenicity of captured tumor cells and screening metabolic inhibitors as anti-metastatic drugs. Furthermore, the platform efficiently detected various aggressive cancer cells in unprocessed whole blood samples with high sensitivity, showing potential for clinical application.     

循环肿瘤细胞体内检测技术及其应用研究

从实体瘤脱落进入血液循环系统的肿瘤细胞即循环肿瘤细胞(CTCs)与肿瘤转移密切相关,因此CTCs检测对癌症患者的诊断、治疗监测、病情评估以及肿瘤转移机制研究具有重要意义.由于CTCs在体内含量极少、异质性、分布不均一,通过体外采血发展的CTCs检测技术虽然已取得很大进展,但仍然面临肿瘤细胞损失、失活、失真以及灵敏度低等...     

Radioactive metal complexes with affinity for tumors. II. Biodistribution of radioactivity in cellular and subcellular fractions of tumor tissues

The 99mTc and 57Co complexes of ethylenediamine-N,N-diacetic acid (EDDA) are accumulated in tumor tissue. The complexes and related radioactive compounds were administered to experimental animals bearing Ehrlich tumor, and the blood, tumor, abscess, and other tissues were separated, fractionated and analyzed. In blood, the EDDA complexes of 99mTc and 57Co were in dialyzable forms, whereas other tumor-nonlocalizing compounds were in undialyzable or protein-bound forms. The tumor/blood and tumor/muscle ratios of the radioactivity showed that the complexes had the high affinity for tumor tissues. Density gradient centrifugation analysis of the ascites tumor tissues showed that a significant amount of the radioactivity of the complexes was present in tumor cells. Subcellular fractionation of solid tumor tissue showed that the radioactivity was present in nuclear fraction.     

A carbohydrate-grafted nanovesicle with activatable optical and acoustic contrasts for dual modality high performance tumor imaging

Activatable molecular systems enabling precise tumor localization are valuable for complete tumor resection. Herein, we report sialic acid-capped polymeric nanovesicles encapsulating the near infrared profluorophore (pNIR@P@SA) for lysosome activation based dual modality tumor imaging. The probe features surface-anchored sialic acid for tumor targeting and a core of near infrared profluorophore (pNIR) which undergoes lysosomal acidity triggered isomerization to give optical and optoacoustic signals upon cell internalization. Imaging studies reveal high-efficiency uptake and signal activation of pNIR@P@SA in subcutaneous tumors and millimeter-sized liver tumor foci in mice. The high tumor-to-healthy organ signal contrasts and discernment of tiny liver tumors from normal liver tissues validate the potential of pNIR@P@SA for high performance optical and optoacoustic imaging guided tumor resection.     

Microfluidic Screening of Circulating Tumor Biomarkers toward Liquid Biopsy

The development of early and personalized diagnostic protocol with rapid response and high accuracy is considered the most promising avenue to advance point-of-care testing for tumor diagnosis and therapy. Given the growing awareness of the limitations of conventional tissue biopsy for gathering tumor information, considerable interest has recently been aroused in liquid biopsy. Among a myriad of analytical approaches proposed for liquid biopsy, microfluidics-based separation and purification techniques possess merits of high throughput, low samples consumption, high flexibility, low cost, high sensitivity, automation capability and enhanced spatio-temporal control. These characteristics endow microfluidics to serve as an emerging and promising tool in tumor diagnosis and prognosis by identifying specific circulating tumor biomarkers. In this review, we will put our focus on three key categories of circulating tumor biomarkers, namely, circulating tumor cells (CTCs), circulating exosomes, and circulating nucleic acids (cNAs), and discuss the significant roles of microfluidics in the separation and analysis of circulating tumor biomarkers. Recent advances in microfluidic separation and analysis of CTCs, exosomes, and cNAs will be highlighted and tabulated. Finally, the current challenges and future niches of using microfluidic techniques in the separation and analysis of circulating tumor biomarkers will be discussed.     

Natural Products in Preventing Tumor Drug Resistance and Related Signaling Pathways

Drug resistance is still an obstacle in cancer therapy, leading to the failure of tumor treatment. The emergence of tumor drug resistance has always been a main concern of oncologists. Therefore, overcoming tumor drug resistance and looking for new strategies for tumor treatment is a major focus in the field of tumor research. Natural products serve as effective substances against drug resistance because of their diverse chemical structures and pharmacological effects. We reviewed the signaling pathways involved in the development of tumor drug resistance, including Epidermal growth factor receptor (EGFR), Renin-angiotensin system (Ras), Phosphatidylinositol-3-kinase/protein kinase B (PI3K/Akt), Wnt, Notch, Transforming growth factor-beta (TGF-β), and their specific signaling pathway inhibitors derived from natural products. This can provide new ideas for the prevention of drug resistance in cancer therapy.     

Cathepsin B‐Specific Metabolic Precursor for In Vivo Tumor‐Specific Fluorescence Imaging

Recently, metabolic glycoengineering with bioorthogonal click reactions has focused on improving the tumor targeting efficiency of nanoparticles as delivery vehicles for anticancer drugs or imaging agents. It is the key technique for developing tumor‐specific metabolic precursors that can generate unnatural glycans on the tumor‐cell surface. A cathepsin B‐specific cleavable substrate (KGRR) conjugated with triacetylated N‐azidoacetyl‐d ‐mannosamine (RR‐S‐Ac₃ManNAz) was developed to enable tumor cells to generate unnatural glycans that contain azide groups. The generation of azide groups on the tumor cell surface was exogenously and specifically controlled by the amount of RR‐S‐Ac₃ManNAz that was fed to target tumor cells. Moreover, unnatural glycans on the tumor cell surface were conjugated with near infrared fluorescence (NIRF) dye‐labeled molecules by a bioorthogonal click reaction in cell cultures and in tumor‐bearing mice. Therefore, our RR‐S‐Ac₃ManNAz is promising for research in tumor‐specific imaging or drug delivery.     

Anti-tumor immunostimulatory effect of heat-killed tumor cells

As a part of our ongoing search for a safe and efficient anti-tumor vaccine, we attempted to determine whether the molecular nature of certain tumor antigens would influence immune responses against tumor cells. As compared with freeze-thawed or formaldehyde-fixed tumor antigens, heat-denatured tumor antigens elicited profound anti-tumor immune responses and greatly inhibited the growth of live tumor cells. The heat-denatured tumor antigens induced a substantial increase in the anti-tumor CTL response in the absence of any adjuvant material. This response appears to be initiated by strong activation of the antigen-presenting cells, which may recognize heat-denatured protein antigens. Upon recognition of the heat-denatured tumor antigens, macrophages and dendritic cells were found to acutely upregulate the expression of co-stimulatory molecules such as B7.2, as well as the secretion of inflammatory cytokines such as IL-12 and TNF-alpha. The results of this study indicate that heat-denatured tumor extracts might elicit protective anti-tumor adaptive immune responses and also raise the possibility that a safe and efficient adjuvant-free tumor vaccine might be developed in conjunction with a dendritic cell-based tumor vaccine.     

A Synthetic Glycopeptide Vaccine for the Induction of a Monoclonal Antibody that Differentiates between Normal and Tumor Mammary Cells and Enables the Diagnosis of Human Pancreatic Cancer

In studies within the realm of cancer immunotherapy, the synthesis of exactly specified tumor‐associated glycopeptide antigens is shown to be a key strategy for obtaining a highly selective biological reagent, that is, a monoclonal antibody that completely differentiates between tumor and normal epithelial cells and specifically marks the tumor cells in pancreas tumors. Mucin MUC1, which is overexpressed in many prevalent cancers, was identified as a promising target for this strategy. Tumor‐associated MUC1 differs significantly from that expressed by normal cells, in particular by altered glycosylation. Structurally defined tumor‐associated MUC1 cannot be isolated from tumor cells. We synthesized MUC1–glycopeptide vaccines and analyzed their structure–activity relationships in immunizations; a monoclonal antibody that specifically distinguishes between human normal and tumor epithelial cells was thus generated.     

Recent research advances of the biomimetic tumor microenvironment and regulatory factors on microfluidic devices: A systematic review

Tumor microenvironment is a multicomponent system consisting of tumor cells, noncancer cells, extracellular matrix, and signaling molecules, which hosts tumor cells with integrated biophysical and biochemical elements. Because of its critical involvement in tumor genesis, invasion, metastasis, and resistance, the tumor microenvironment is emerging as a hot topic of tumor biology and a prospective therapeutic target. Unfortunately, the complex of microenvironment modeling in vitro is technically challenging and does not effectively generalize the local tumor tissue milieu. Recently, significant advances in microfluidic technologies have provided us with an approach to imitate physiological systems that can be utilized to mimic the characterization of tumor responses with pathophysiological relevance in vitro. In this review, we highlight the recent progress and innovations in microfluidic technology that facilitates the tumor microenvironment study. We also discuss the progress and future perspective of microfluidic bionic approaches with high efficiency for the study of tumor microenvironment and the challenges encountered in cancer research, drug discovery, and personalized therapy.